Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
N/A N=300 Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta
Liver Cancer
Primary: Serum Aflatoxin Level in Liver Cancer Patients — 7.96; 6.10; 4.13 ng\ml
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
N/A N=105 Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
Hepatocellular Carcinoma
Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005
Phase 2 N=12 [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
N/A N=402 HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma
Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale
Phase 2 N=32 Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants
Phase 1 N=31 A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
Cancer
Primary: Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib — 23.6; 30.7; 30.5; 20.5 micromolar
Phase 1 N=55 A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Carcinoma, Hepatocellular · Biliary Tract Cancer · Secondary Liver Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0; 0; 2 Participants
N/A N=76 Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Hepatocellular Carcinoma
Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 4 N=96 Hepatic Xenetix-CT Perfusion
Hepatocellular Carcinoma
Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
Phase 2 N=26 Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Primary Liver Carcinoma
Primary: Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) — 15 Participants
Phase 2 N=40 Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Hepatocellular Cancer
Primary: Time to Progression — 7.7 Months
Phase 2 N=146 A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
Phase 2 N=30 Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: One-Year Overall Survival Rate — 16 Participants
Phase 2 N=76 A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma · Liver Cancer
Primary: Tumor Response — 0; 7; 47; 11 Participants
Phase 2 N=50 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
Phase 2 N=54 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Phase 2 N=34 A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
Hepatic Cancer
Primary: Treatment Response — 16; 14; 4 Participants
Phase 2 N=19 A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants
Phase 2 N=60 Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular Carcinoma
Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001
N/A N=76 Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Two Year Overall Survival — 65; 68 percentage of participants
N/A N=407 Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
Cirrhosis of Liver
Primary: Detection Rate of Patients With HCC — 27.9; 86.0 percentage of HCC detected on each exam — p=<0.01
Phase 2 N=137 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants